Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
More News
Pulmonx (LUNG) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +14.29% and +2.34%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts
Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) has received an average rating of "Hold" from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold reco...
MarketBeat
Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen lowered Pulmonx from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
Pulmonx's (LUNG) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital reiterated a "buy" rating and issued a $14.00 price target on shares of Pulmonx in a report on Thursday...
MarketBeat
Pulmonx Q1 Earnings Call Highlights
Pulmonx (NASDAQ:LUNG) reported first-quarter 2026 worldwide revenue of $20.6 million, as management emphasized early progress on commercial execution, continued advancement of its AeriSeal clinical program, and actions to reduce spending and extend its cash runway. Executives reiterated full-year 20...
MarketBeat
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 0.00% and +2.52%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pulmonx (NASDAQ:LUNG) Releases Quarterly Earnings Results, Meets Expectations
Pulmonx (NASDAQ:LUNG - Get Free Report) released its earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, hitting analysts' consensus estimates of ($0.33). Pulmonx had a...
MarketBeat

Advertisement|Remove ads.